Comparative study of postoperative analgesic effects of parecoxib versus ketorolac and placebo in cervical disc surgery

Egyptian Journal of Anaesthesia

Volumn 19, Issue 2, 2003, Pages 179-182

  Hegazy, Essmat M ^a   El Hady, Naglaa Abd ^a   Abdallah, Mai Wedad ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Cyclooxygenase 2 inhibitors; Ketorolac; Parecoxib; Postoperative pain control

Indexed keywords

ATRACURIUM; ATROPINE; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL; ISOFLURANE; KETOROLAC; MORPHINE; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROPOFOL; VALDECOXIB;

ADULT; ANALGESIC ACTIVITY; ARTICLE; BLEEDING; BLEEDING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG UTILIZATION; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DYSFUNCTION; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPINE SURGERY;

EID: 0242331312     PISSN: 11101849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kuehl FA, Egan RW: Prostaglandins, arachidonic acid and inflammation. Science 1980;210:978-984.
2. Hawkey CJ: New drug classes - COX-2 inhibitors. Lancet 1999;353:307-314.
3. Ormord D, Wellington K, Wagstaff AJ: Valdecoxib. Drugs 2002;62(14):2059-2071.
4. Feldman HI, Kinman JL, Berlin JA, et al.: Parenteral ketorolac: The risk for acute renal failure. Ann Intern Med 1997;126:193-199.
5. Gillis JC, Brogden RN: Ketorolac: A reappraisal of its pharmacodynamic and pharmacokinetic proper-ties and therapeutic use in pain management. Drugs 1997;53:139-188.
6. Strom BL, Berlin JA, Kinman JL, et al.: Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. JAMA 1996;275:376-382.
7. Talley JJ, Bertenshaw SR, Brown DL, et al.: N[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl] sulfonyl] propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000;43: 1661-1663.
8. Daniels SE, Kuss M, Mehlisch DR, et al.: Pharmacokinetic and efficacy evaluation of intravenous parecoxib in a postsurgical dental pain model. Clin Pharmacol Ther 2000;67:1-8.
9. Rasmussen GL, Steckner K, Hogue CW, et al.: A comparative analgesic efficacy study of parecoxib sodium, a new injectable COX-2 specific inhibitor, in post-orthopedic surgery patients. Proc Am Pain Soc 2001;A776.
10. Kenaan CA, Bikhazi GB, Deepika K, et al.: Analgesic activity and safety of parecoxib in postsurgical patients: An interium report. Anesth Analg 2001;92:S257.
11. Jain KK: Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs 2000;9:2717-2723.
12. Ivy AC, Nelson D, Buchet G: The standardization of certain factors in the cutaneous venostatis bleeding time technique. J Lab Clin Med 1941;26:1812.
13. Kehlet H, Dahl JB: The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 1993;77:1048-1056.
14. Burns JW, Aitken HA, Bullingham RES: Double-blind comparison of the morphine-sparing effect of continuous and intermittent i.m. administration of ketorolac. Br J Anaesth 1991;67:235-238.
15. Parker RK, Holtmann B, Smith I, White PF: Use of ketorolac after lower abdominal surgery: Effect on analgesic requirement and surgical outcome. Anesthesiology 1994;80:6-12.
16. Sevarino FB, Sinatra RS, Paige D: The efficacy of intramuscular ketorolac in combination with intravenous PCA morphine for postoperative pain relief. J Clin Anesth 1992;4:285-288.
17. Lewis S: Ketorolac in Europe [letter]. Lancet 1994;343:784.
18. Seibert K, Zhang Y, Leahy K: Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci 1994;91:12013-12017.
19. Barton SF, Langeland FF, Snabes MC, et al.: Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynaecologic laparotomy surgery. Anesthesiology 2002;97:306-314.
20. Daniels SE, Grossman EH, Kuss ME, et al.: A double-blind, randomized comparison of intramus-cularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001;23:1018-1031.
21. Rasmussen GL, Steckner K, Hogue C, et al.: Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop 2002;31: 336-343.
22. Harris SI, Kuss M, Hubbard RC, Goldstein JL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2 specific inhibitor, compared with ketorolac, naproxen and placebo. Clin Ther 2001;23:1422-1428.
23. Noveck RJ, Kuss ME, Qian J, et al.: Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirin-mediated platelet function. Reg Anesth Pain Med 2001;26 (Suppl):19.
24. Brian KT, Daren BN, Gregory WB, et al.: Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anaesthesia. Anesth Analg 1996;82:1176-1181.
25. Splinter WM, Rhine EJ, Roberts DW, et al.: Perioperative ketorolac increases bleeding after tonsillectomy in children. Can J Anaesth 1996;43: 560-563.